Lixte Biotechnology Changes HQ, Reports Officer/Director Updates
Ticker: LIXT · Form: 8-K · Filed: Dec 27, 2024 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | 8-K |
| Filed Date | Dec 27, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-changes, office-relocation
Related Tickers: LIXT
TL;DR
Lixte Biotech moved its HQ to Pasadena, CA and made exec/board changes.
AI Summary
Lixte Biotechnology Holdings, Inc. announced on December 23, 2024, a change in its principal executive offices to 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101. The company also reported changes related to director departures, elections, and officer appointments, along with compensatory arrangements for certain officers.
Why It Matters
A change in principal executive offices can signal operational shifts or strategic realignments for the company. Updates on directors and officers are crucial for understanding corporate governance and leadership.
Risk Assessment
Risk Level: medium — Changes in executive and director positions, along with office relocations, can introduce uncertainty regarding future strategy and operations.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer
- December 23, 2024 (date) — Date of earliest event reported
- 680 East Colorado Boulevard , Suite 180 Pasadena , California 91101 (location) — New principal executive offices
- 001-39717 (company_id) — SEC File Number
FAQ
What is the new address for Lixte Biotechnology Holdings, Inc.'s principal executive offices?
The new address for Lixte Biotechnology Holdings, Inc.'s principal executive offices is 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 23, 2024.
What are the main items covered in this 8-K filing?
This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What was the former company name or former SEC file number if any?
The filing mentions a former company name 'SRKP 7 INC' with a date of name change on 20050803, but does not list a former SEC file number.
What is the SIC code for Lixte Biotechnology Holdings, Inc.?
The Standard Industrial Classification (SIC) code for Lixte Biotechnology Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 381 words · 2 min read · ~1 pages · Grade level 13.2 · Accepted 2024-12-27 16:05:20
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-24-052249.txt ( ) — 250KB
- lixt-20241223.xsd (EX-101.SCH) — 3KB
- lixt-20241223_def.xml (EX-101.DEF) — 29KB
- lixt-20241223_lab.xml (EX-101.LAB) — 36KB
- lixt-20241223_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 27, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan Chief Executive Officer